Literature DB >> 27699242

Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.

Vincent A Jourdain, Chris C Tang, Florian Holtbernd, Christian Dresel, Yoon Young Choi, Yilong Ma, Vijay Dhawan, David Eidelberg.   

Abstract

Levodopa-induced dyskinesia (LID) is the most common, disruptive complication of Parkinson's disease (PD) pharmacotherapy, yet despite decades of research, the changes in regional brain function underlying LID remain largely unknown. We previously found that the cerebral vasomotor and metabolic responses to levodopa are dissociated in PD subjects. Nonetheless, it is unclear whether levodopa-mediated dissociation is exaggerated in LID or distinguishes LID from non-LID subjects. To explore this possibility, we used dual-tracer positron emission tomography to quantify regional cerebral blood flow and metabolic activity in 28 PD subjects (14 LID, 14 non-LID), scanned before and during intravenous levodopa infusion. Levodopa-mediated dissociation was most prominent in the posterior putamen (P < 0.0001) and greater in LID than in non-LID and test-retest subjects. Strikingly, LID subjects also showed increased sensorimotor cortex (SMC) activity in the baseline, unmedicated state. Imaging data from an independent PD sample (106 subjects) linked these differences to loss of mesocortical dopamine terminals in advanced patients. In aggregate, the data suggest that LID results from an overactive vasomotor response to levodopa in the putamen on a background of disease-related increases in SMC activity. LID may thus be amenable to treatment that modulates the function of these 2 regions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27699242      PMCID: PMC5033758          DOI: 10.1172/jci.insight.86615

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  52 in total

1.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

Review 2.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder.

Authors:  Ping Wu; Huan Yu; Shichun Peng; Yves Dauvilliers; Jian Wang; Jingjie Ge; Huiwei Zhang; David Eidelberg; Yilong Ma; Chuantao Zuo
Journal:  Brain       Date:  2014-10-22       Impact factor: 13.501

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Identification of disease-related spatial covariance patterns using neuroimaging data.

Authors:  Phoebe Spetsieris; Yilong Ma; Shichun Peng; Ji Hyun Ko; Vijay Dhawan; Chris C Tang; David Eidelberg
Journal:  J Vis Exp       Date:  2013-06-26       Impact factor: 1.355

6.  Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

Authors:  T Ishikawa; V Dhawan; T Chaly; C Margouleff; W Robeson; J R Dahl; F Mandel; P Spetsieris; D Eidelberg
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

7.  Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation.

Authors:  Hideo Mure; Chris C Tang; Miklos Argyelan; Maria-Felice Ghilardi; Michael G Kaplitt; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2012-02-22       Impact factor: 6.167

8.  Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).

Authors:  Peter A Lewitt; Robert A Hauser; Mei Lu; Anthony P Nicholas; William Weiner; Nicholas Coppard; Mika Leinonen; Juha-Matti Savola
Journal:  Neurology       Date:  2012-06-27       Impact factor: 9.910

9.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

10.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

View more
  8 in total

1.  Network Structure and Function in Parkinson's Disease.

Authors:  Ji Hyun Ko; Phoebe G Spetsieris; David Eidelberg
Journal:  Cereb Cortex       Date:  2018-12-01       Impact factor: 5.357

2.  Neuroprotective Effects of Echinacoside on Regulating the Stress-Active p38MAPK and NF-κB p52 Signals in the Mice Model of Parkinson's Disease.

Authors:  Jingsi Zhang; Zhennian Zhang; Jun Xiang; Min Cai; Zhonghai Yu; Xiangting Li; Ting Wu; Dingfang Cai
Journal:  Neurochem Res       Date:  2016-12-15       Impact factor: 3.996

3.  Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.

Authors:  Vincent A Jourdain; Katharina A Schindlbeck; Chris C Tang; Martin Niethammer; Yoon Young Choi; Daniel Markowitz; Amir Nazem; Dominic Nardi; Nicholas Carras; Andrew Feigin; Yilong Ma; Shichun Peng; Vijay Dhawan; David Eidelberg
Journal:  JCI Insight       Date:  2017-10-19

4.  Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia.

Authors:  Koji Fujita; Shichun Peng; Yilong Ma; Chris C Tang; Matthew Hellman; Andrew Feigin; David Eidelberg; Vijay Dhawan
Journal:  J Neurol       Date:  2021-01-27       Impact factor: 4.849

5.  Dynamic 18F-FPCIT PET: Quantification of Parkinson's disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session.

Authors:  Shichun Peng; Chris Tang; Katharina Schindlbeck; Yaacov Rydzinski; Vijay Dhawan; Phoebe G Spetsieris; Yilong Ma; David Eidelberg
Journal:  J Nucl Med       Date:  2021-03-19       Impact factor: 11.082

6.  Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia.

Authors:  Renata P Lerner; Veronica Francardo; Koji Fujita; Zisis Bimpisidis; Vincent A Jourdain; Chris C Tang; Stephen L Dewey; Thomas Chaly; M Angela Cenci; David Eidelberg
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

Review 7.  On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Henrik Jörntell; Per Petersson
Journal:  J Neural Transm (Vienna)       Date:  2018-04-27       Impact factor: 3.575

8.  Significance and Translational Value of High-Frequency Cortico-Basal Ganglia Oscillations in Parkinson's Disease.

Authors:  Per Petersson; Pär Halje; M Angela Cenci
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.